Business Context and Reporting Period
Company: E. I. du Pont de Nemours and Company (DuPont)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Year ended December 31, 2001
Business Overview: DuPont is a global science and technology leader operating in high-performance materials, synthetic fibers, electronics, specialty chemicals, agriculture, and biotechnology. Operations span approximately 75 countries with about 50% of sales generated outside the United States. Total worldwide employment was approximately 79,000 at year-end 2001.
Strategic Realignment: In February 2002, the company announced a restructuring into five market- and technology-focused growth platforms and plans to create a Textiles and Interiors subsidiary, potentially separating it by year-end 2003. The 2001 report reflects the prior organizational structure of eight reportable segments.
Key Financial Metrics
Note: The provided text is a table of contents and narrative summary. Specific numerical values for revenue, profit, cash flow, and debt are incorporated by reference to the 2001 Annual Report to Stockholders (Exhibit 13) and are not present in the source text.
- Revenue & Profit: Specific consolidated sales, net income, and operating income figures are not listed in this text. Segment financial data is referenced as being located in Note 32 of Exhibit 13.
- Market Capitalization: As of March 7, 2002, the aggregate market value of voting stock held by nonaffiliates was approximately $46.6 billion.
- Share Count: 992,953,510 shares of common stock were outstanding as of March 7, 2002 (excluding 87,041,427 shares of treasury stock).
- Capacity Utilization: Sales as a percent of capacity were 78% in 2001, compared to 81% in 2000 and 83% in 1999.
- Intellectual Property: The company owns over 20,000 worldwide patents and over 14,000 patent applications. In 2001, it was granted nearly 500 U.S. patents and over 1,800 international patents.
Material Changes and Significant Events
- Sale of Pharmaceuticals: On October 1, 2001, DuPont sold its Pharmaceuticals business to Bristol-Myers Squibb. DuPont retained interests in the Cozaar and Hyzaar brands, licensing marketing rights to Merck & Co. Inc. Effective Q4 2001, the Pharmaceuticals segment reflects only the results of this collaboration.
- Discontinued Operations: The company completed the divestiture of its petroleum business, Conoco Inc., in 1999. This business is reported as discontinued operations.
- Organizational Restructuring: The company moved from eight reportable segments to a new structure of five growth platforms (Electronic & Communication Technologies, Performance Materials, Coatings & Color Technologies, Safety & Protection, and Agriculture & Nutrition) announced in February 2002.
- Benlate Litigation: DuPont discontinued the manufacture and sale of Benlate fungicide in 2001. Approximately 110 lawsuits remain pending, including a Florida jury verdict finding DuPont liable for approximately $88.5 million (subject to appeal).
Guidance, Risks, and Contingencies
Legal Proceedings:
- Benlate Litigation: Pending cases include crop damage claims and allegations of fraud. A Florida jury verdict of $88.5 million is under appeal. Ecuadorian shrimp farmers have obtained adverse judgments totaling approximately $30 million, which DuPont is appealing.
- Monsanto Litigation: A lawsuit regarding the license for Roundup Ready soybeans was filed by Monsanto. A district court ruled that DuPont's acquisition of Pioneer terminated the license, but the case is on appeal. An adverse outcome could result in a one-time noncash charge to earnings.
- Environmental: DuPont reached an agreement to settle a 1997 hydrogen fluoride release in Louisville, Kentucky, for $1,102,000. Additionally, a Delaware consent order regarding the Edgemoor facility requires remedial actions estimated at $12.4 million.
Risk Factors:
- Raw Material Costs: Earnings growth is sensitive to increases in oil, natural gas, and hydrocarbon feedstock costs.
- Global Operations: Approximately 50% of sales are outside the U.S., exposing the company to foreign currency fluctuations, political instability, and economic downturns in key regions.
- Seasonality: Agriculture & Nutrition sales are strongest in the first half of the year; Performance Coatings & Polymers are affected by motor vehicle build cycles.
- Product Pipeline: Growth depends on the successful development and regulatory approval of new products.
Investor Verification Checklist
- Verify the specific consolidated revenue, net income, and cash flow figures in the 2001 Annual Report to Stockholders (Exhibit 13), as they are not detailed in this filing text.
- Review the status of the Monsanto vs. Pioneer/DuPont litigation regarding Roundup Ready soybeans, as an adverse ruling could impair intangible assets.
- Monitor the outcome of the Benlate litigation appeals, particularly the $88.5 million Florida verdict and the Ecuadorian shrimp farm cases.
- Assess the impact of the February 2002 strategic realignment on future segment reporting and the potential separation of the Textiles & Interiors business.
- Confirm the adequacy of environmental reserves, specifically regarding the $12.4 million Edgemoor facility remediation and ongoing natural resource damage assessments.